Organisation paid for research Program year 2025 Source: CMS Open Payments

University Physicians & Surgeons Inc

Neither a doctor nor a teaching hospital

Research payments

$149,160

73 payments

Through program year 2025, University Physicians & Surgeons Inc is reported as receiving $149,160 in research payments, across 73 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $28,987 15
2024 Research $31,788 5
2023 Research $44,141 25
2022 Research $10,454 1
2021 Research $6,897 1
2020 Research $6,181 4
2019 Research $20,712 22

Breakdown

Who paid Research payments · program years 2019–2025
  1. LivaNova USA, Inc. $45,032 29 payments
  2. Boston Scientific Corporation $26,014 10 payments
  3. Shire North American Group Inc $20,712 22 payments
  4. Bausch Health US, LLC $18,200 2 payments
  5. Genentech, Inc. $15,670 4 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $13,079 5 payments
  7. Alexion Pharmaceuticals, Inc. $10,454 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $29,147 10 payments
  2. Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of Hyqvia in Pediatric Pidd Subjects $27,609 23 payments
  3. Lux-Dx Trends $21,014 8 payments
  4. Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) $18,200 2 payments
  5. Recover $15,885 19 payments
  6. UC P3: Double-Blind Treat Straight Through $15,670 4 payments
  7. A Ph 3 Open label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients with COVID 19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome $10,454 1 payment
  8. Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of Hyqvia in Pediatric Pidd Subjects $6,181 4 payments
  9. Lux DX Trends $5,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record